miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2

MicroRNAs (miRNAs) have emerged as critical modulators of carcinogenesis and tumor progression. In the present work, we sought to identify the biological function of miR-155 as well as its underlying mechanism in clear cell renal cell carcinoma (ccRCC). We examined the expression of miR-155 in clear cell RCC (ccRCC) and adjacent normal tissues and then explored the roles of miR-155 both in vitro and in vivo. The results of this analysis indicated that miR-155 activity was significantly upregulated in ccRCC tissues compared with the corresponding normal tissues. miR-155 was associated with ccRCC aggressiveness in both cell lines and clinical specimens, and a specific and inverse correlation between miR-155 and E2F2 expression was found in human ccRCC samples. Overexpression of miR-155 in 786-O cells decreased E2F2 expression while reduction of miR-155 by anti-miR-155 in ACHN cells elevated E2F2 expression. Re-expression of E2F2 in 786-O cells repressed the cell migration/invasion abilities elevated by miR-155, whereas knockdown of E2F2 in ACHN cells restored these cellular functions hampered by the miR-155 inhibitor. Using Western blot and luciferase reporter assays, we determined that E2F2 was a direct target of miR-155. Taken together, the in vitro and in vivo results demonstrate that miR-155 functions as a tumor-promoting miRNA by targeting E2F2 in ccRCC.

[1]  Zhiwen Xu,et al.  The network of microRNAs, transcription factors, target genes and host genes in human renal cell carcinoma , 2014, Oncology letters.

[2]  Ryan M. O’Connell,et al.  miR-155-SOCS1 as a Functional Axis: Satisfying the Burden of Proof. , 2015, Immunity.

[3]  V. Khoo,et al.  Radiotherapy for renal-cell carcinoma. , 2014, The Lancet. Oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[5]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  Jean-Jacques Patard,et al.  EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.

[7]  G. Bhanot,et al.  Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.

[8]  Xin Ma,et al.  Overexpression of E2F1 Promotes Tumor Malignancy And Correlates with TNM Stages in Clear Cell Renal Cell Carcinoma , 2013, PloS one.

[9]  Nidhi Sharma,et al.  Cell proliferation in the absence of E2F1-3. , 2011, Developmental biology.

[10]  W. Krek,et al.  Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer , 2015, Oncotarget.

[11]  M. Malumbres,et al.  E2F2 represses cell cycle regulators to maintain quiescence , 2008, Cell cycle.

[12]  T. Litman,et al.  STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma , 2013, Cell cycle.

[13]  Tianxin Lin,et al.  MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1 , 2015, Oncotarget.

[14]  You-cai Zhao,et al.  MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma , 2015, Scientific Reports.

[15]  Xing-Sui Lu,et al.  miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression , 2014, Clinical Cancer Research.

[16]  V. Ambros,et al.  Role of MicroRNAs in Plant and Animal Development , 2003, Science.

[17]  Suzanne D Turner,et al.  Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation , 2015, The Journal of pathology.

[18]  Hong-bing Chen,et al.  Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer , 2015, Tumor Biology.

[19]  Xiangjun Lyu,et al.  Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma , 2015, Journal of Translational Medicine.

[20]  E2f1, E2f2, and E2f3 Control E2F Target Expression and Cellular Proliferation via a p53-Dependent Negative Feedback Loop , 2012, Molecular and Cellular Biology.

[21]  G. Luo,et al.  miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma , 2015, Oncotarget.

[22]  David S. Park,et al.  Unique Requirement for Rb/E2F3 in Neuronal Migration: Evidence for Cell Cycle-Independent Functions , 2007, Molecular and Cellular Biology.

[23]  F. Christians,et al.  E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. , 2001, Genes & development.

[24]  Xiaokun Zhao,et al.  microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells , 2012, Molecular medicine reports.

[25]  M. Seto,et al.  Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.

[26]  L. Naldini,et al.  A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. , 2013, Blood.

[27]  Hans Lehrach,et al.  MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy , 2009, Journal of cellular and molecular medicine.

[28]  N. Concin,et al.  Expression of the E2F Family of Transcription Factors and Its Clinical Relevance in Ovarian Cancer , 2006, Annals of the New York Academy of Sciences.

[29]  D. Raggi,et al.  Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma , 2015, Therapeutic Advances in Urology.

[30]  Xiao Han,et al.  Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma. , 2015, International journal of clinical and experimental pathology.

[31]  T. Choueiri,et al.  Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. , 2015, European journal of cancer.

[32]  Yurong Fu,et al.  Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues , 2010, Journal of Cancer Research and Clinical Oncology.

[33]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[34]  Yiliang Zhang,et al.  Hepatitis C virus‐induced up‐regulation of microRNA‐155 promotes hepatocarcinogenesis by activating Wnt signaling , 2012, Hepatology.

[35]  J. DeGregori,et al.  The genetics of the E2F family of transcription factors: shared functions and unique roles. , 2002, Biochimica et biophysica acta.

[36]  Jian Gao,et al.  TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. , 2015, Cancer letters.

[37]  S. Oudard,et al.  The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma , 2015, Current opinion in urology.

[38]  N. Dyson,et al.  The E2F transcriptional network: old acquaintances with new faces , 2005, Oncogene.

[39]  T. Sellers,et al.  Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer , 2013, Oncogene.

[40]  H. Mankin,et al.  MicroRNA-155 expression is independently predictive of outcome in chordoma , 2015, Oncotarget.

[41]  Tao Xi,et al.  miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2 , 2014, Biotechnology Letters.

[42]  Shuai Jiang,et al.  MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.

[43]  I. Ernberg,et al.  Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. , 2015, International journal of clinical and experimental medicine.

[44]  Hong-zhao Li,et al.  MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. , 2015, Urologic oncology.

[45]  Umberto Capitanio,et al.  Renal Cancer , 2011 .

[46]  B. Escudier,et al.  mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response , 2015, European Radiology.

[47]  N. A. Walton,et al.  Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis , 2007, Proceedings of the National Academy of Sciences.